CSL Seqirus

Tweet this page
<
2023
2024
>
Registration as it was on 01 Nov 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

400,000€ - 499,999€

Financial year: Jul 2023 - Jun 2024

Lobbyists (Full time equivalent)

1.1 Fte (4)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    CSL Seqirus

    EU Transparency Register

    235418549954-90 First registered on 24 Apr 2023

    Goals / Remit

    At CSL Seqirus we are driven by just one goal - to lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences. Every year our influenza vaccines help protect millions of people. We find solutions to big, complex, challenging problems, and we see the results in the world around us. Then we do it all over again the following year. CSL Seqirus is one of the largest influenza vaccine companies. We were created when our parent company, CSL Limited, acquired the Novartis influenza vaccine business and combined it with vaccine subsidiary, BioCSL.

    Main EU files targeted

    EU Health Data Space
    EU Health Emergency Response Authority
    EU Pharmaceutical legislation
    EU Emergency Authorisation Regulation
    ECDC and EMA

    Address

    Head Office
    CSL SeqirusLevel 3, 8AA, 29 Market St
    Maidenhead SL6 8AD
    UNITED KINGDOM
    EU Office
    CSL SeqirusLevel 3, 8AA, 29 Market St
    Maidenhead SL6 8AD
    UNITED KINGDOM

    Website

    https://www.seqirus.com/

  • People

    Total lobbyists declared

    4

    Employment timeLobbyists
    50%1
    25%2
    10%1

    Lobbyists (Full time equivalent)

    1.1

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 15 Jan 2025

    Name Start date End Date
    Dirk Ulrich HOFMANN 05 Jan 2024 04 Oct 2024

    Complementary Information

    N/A

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Vaccines Europe

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jul 2023 - Jun 2024

    Lobbying costs for closed financial year

    400,000€ - 499,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    acumen public affairs 100,000€ - 199,999€

    Intermediaries for current year

    Name
    acumen public affairs

    Closed year Costs

    400,000€ - 499,999€

    Other financial info

    N/A

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    As members of the trade association Vaccines Europe, we have conducted an EU Flu Day campaign in 2020, 2021, 2022, 2023 and in 2024.

    In 2023 we sponsored an event at the European Parliament, hosted by MEP Stelios Kympouropoulos, on Real World Evidence for healthcare policymaking.

    CSL Seqirus also makes grants to the European Scientific Working group on Influenza (ESWI) to support influenza scientific exchange and education and young scientist awards.

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard